The trajectory of Sildenafil presents a complex picture for shareholders. While the initial release generated substantial returns, the expiration of its intellectual property protection opened the avenue to off-brand alternatives, dramatically diminishing market share. This presents a unique dilemma for firms relying on comparable blockbuster medic

The history of Viagra, and its parent company copyright, presents a complex case study for investors. Originally a blockbuster drug, yielding billions in revenue , its exclusivity period created a wave of knock-off medications, significantly eroding its market share . While certain pharmaceutical companies may seek to capitalize on male sexual dysf